Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

New SHTAC publication on tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection

Published: 1 July 2010
New SHTAC report

A summary of the evidence review group report on tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection, produced as past of the Single Technology Appraisal process, is now available.

This paper, published as a supplement to the Health Technology Assessment monograph series, presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, in accordance with the licensed indication, based upon evidence submission from Gilead to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×